Stock News

Oaktop Capital Management Ii LP Holding in Celgene Corp Com (CELG) Trimmed by $8.02 Million

Celgene Corporation (NASDAQ:CELG) LogoInvestors sentiment decreased to 0.71 in Q2 2018. Its down 0.08, from 0.79 in 2018Q1. It dived, as 68 investors sold CELG shares while 495 reduced holdings. 98 funds opened positions while 300 raised stakes. 476.86 million shares or 7.08% less from 513.18 million shares in 2018Q1 were reported. Confluence Wealth Mngmt Ltd Com accumulated 3,252 shares. Of Toledo Na Oh has invested 0.14% in Celgene Corporation (NASDAQ:CELG). Principal Financial Group stated it has 0.08% of its portfolio in Celgene Corporation (NASDAQ:CELG). Comerica Bank & Trust accumulated 0.12% or 204,244 shares. House Limited Com stated it has 0.65% of its portfolio in Celgene Corporation (NASDAQ:CELG). Janney Capital Management Limited, Pennsylvania-based fund reported 4,040 shares. Community National Bank Na reported 5,235 shares. Mariner Ltd Liability Corp reported 107,273 shares. Sequoia Advisors Llc holds 0.03% in Celgene Corporation (NASDAQ:CELG) or 3,852 shares. Dimensional Fund Ltd Partnership has invested 0.06% of its portfolio in Celgene Corporation (NASDAQ:CELG). Everett Harris And Ca invested in 3,220 shares. Keybank National Association Oh accumulated 353,976 shares. Cullinan Assocs owns 63,915 shares. Aqr Ltd Liability reported 2.95 million shares or 0.24% of all its holdings. B & T Dba Alpha reported 0.48% stake.

Since June 4, 2018, it had 0 buys, and 2 insider sales for $2.43 million activity. LOUGHLIN JAMES J sold $1.40 million worth of Celgene Corporation (NASDAQ:CELG) on Monday, June 4.

Oaktop Capital Management Ii Lp decreased its stake in Celgene Corp Com (CELG) by 4.69% based on its latest 2018Q2 regulatory filing with the SEC. Oaktop Capital Management Ii Lp sold 101,559 shares as the company’s stock rose 12.17% with the market. The hedge fund held 2.06M shares of the major pharmaceuticals company at the end of 2018Q2, valued at $163.99M, down from 2.17 million at the end of the previous reported quarter. Oaktop Capital Management Ii Lp who had been investing in Celgene Corp Com for a number of months, seems to be less bullish one the $51.76 billion market cap company. The stock decreased 1.61% or $1.21 during the last trading session, reaching $74.02. About 4.13M shares traded. Celgene Corporation (NASDAQ:CELG) has declined 38.90% since November 10, 2017 and is downtrending. It has underperformed by 54.52% the S&P500.

More notable recent Celgene Corporation (NASDAQ:CELG) news were published by: which released: “3 Cancer Stocks to Watch in December” on November 07, 2018, also with their article: “Does Celgene Tickle Your Buygene?” published on October 30, 2018, published: “Celgene Corporation 2018 Q3 – Results – Earnings Call Slides” on October 25, 2018. More interesting news about Celgene Corporation (NASDAQ:CELG) were released by: and their article: “Celgene: Money Will Flow Back” published on November 07, 2018 as well as‘s news article titled: “Brief Take On Why I Like Celgene” with publication date: October 29, 2018.

Celgene Corporation (NASDAQ:CELG) Ratings Coverage

Among 6 analysts covering Celgene (NASDAQ:CELG), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Celgene has $16300 highest and $91 lowest target. $118.67’s average target is 60.32% above currents $74.02 stock price. Celgene had 8 analyst reports since May 23, 2018 according to SRatingsIntel. The stock has “Equal-Weight” rating by Morgan Stanley on Friday, July 13. The rating was maintained by Cantor Fitzgerald on Thursday, May 31 with “Hold”. The stock has “Buy” rating by Oppenheimer on Friday, May 25. The company was upgraded on Wednesday, May 23 by Bernstein. The firm earned “Buy” rating on Monday, June 18 by Standpoint Research. On Wednesday, May 23 the stock rating was downgraded by Argus Research to “Hold”. As per Friday, July 27, the company rating was maintained by Morgan Stanley.

Celgene Corporation (NASDAQ:CELG) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *